Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-17T18:03:59.988Z Has data issue: false hasContentIssue false
  • English
  • Français

Are there specific care requirements for patients with schizophrenia and diabetes or with a risk of diabetes?

Published online by Cambridge University Press:  16 April 2020

P. Thomas ,
P. Raymondet ,
B. Charbonnel  and
G. Vaiva
P. Thomas*
Affiliation:
FRE CNRS-2627-Psychiatry Department, CHRU Lille, 59037Lille, France
P. Raymondet
Affiliation:
CHI Toulon-La-Seyne-sur-Mer, Hôpital, rue Chalucet, BP 1412, 83056Toulon cedex, France
B. Charbonnel
Affiliation:
Clinique d'endocrinologie, Nantes cedex, France
G. Vaiva
Affiliation:
FRE CNRS-2627-Psychiatry Department, CHRU Lille, 59037Lille, France Inserm U513, Créteil and Psychiatry Department, CHRU 59037Lille, France
*
*Corresponding author. E-mail address: pthomas@chru-lille.fr (P. Thomas); bernard.charbonnel@sante.univ-nantes.fr (B. Charbonnel).
Get access

Abstract

An interactive workshop was held to discuss the risk of diabetes in patients with schizophrenia, to evaluate the available data concerninghow such patients should be managed in terms of minimising the risk of diabetes and of optimising their care where diabetes to develop. The subjects discussed covered monitoring of risk factors, education about lifestyle and the risk of diabetes, patient care and treatment options, and interfaces between psychiatry and diabetology. The workshop noted that all patients with a diagnosis of schizophrenia had an elevated risk of developing diabetes and that this needed to be reflected in the follow-up of the patients in order to reduce the chances of the emergence of disease. The risk of diabetes is complicated by the presence of other risk factors and the intensity of the diabetes prevention programme needs to reflect adequately the overall risk. The most important prevention methods relate to lifestyle changes that patients with schizophrenia may be spontaneously unlikely to adopt and therefore necessitate the implementation of specific education measures aimed at patients and their families. The workshop proposed follow-up intensities, monitoring procedures and prevention programmes stratified according to the risk of developing diabetes. It was not considered that there was sufficient data available to orientate treatment choices between individual antipsychotic drugs according to the potential risk of developing diabetes.

Keywords

SchizophreniaDiabetesPatient
Type
Research Article
Information
European Psychiatry , Volume 20 , Issue S4 , December 2005 , pp. S358 - S363
Copyright
Copyright © European Psychiatric Association 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

ADA (American Diabetic Association) Screening for diabetes. Diabetes Care. 2002; 25 Suppl 1: S21–4CrossRefGoogle Scholar
Alberti K.G.M.N., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. 1999 http://whglibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf"Google Scholar
Casadebaig, F.Philippe, A.Guillaud-Bataille, J.M.Gausset, M.E.Quemada, N.Terra, J.L.Schizophrenic patients: physical health and access to somatic care. Eur Psychiatry. 1997; 12: 289–93CrossRefGoogle ScholarPubMed
Cavazzoni P, Hornbuckle K, Carlson C, Wu J, Kotsanos J, Holman R,Diabetes mellitus and antipsychotic treatment in the United Kingdom. Poster NCDEU 2002 Section I-32. http://www.nimh.nih.gov/ncdeu/posterabstracts.cfm.CrossRefGoogle Scholar
Citrome, L.L.Efficacy should drive atypical antipsychotic treatment. BMJ. 2003; 326: 283–4CrossRefGoogle ScholarPubMed
Dixon, L.Weiden, P.Delahunty, J.Goldberg, R.Postrado, L.Lucksted, A., et al.Prevalence on correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000; 26: 903–12CrossRefGoogle ScholarPubMed
FDA 2003. http://www.fda.gov/default.htm.Google Scholar
Gianfrancesco, F.D.Grogg, A.L.Mahmoud, R.A.Wang, R.H.Nasrallah, H.A.Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plandatabase. J Clin Psychiatry. 2002; 63: 920–930CrossRefGoogle Scholar
Harris, S.B.Lank, C.N.Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular riskfactors. Can Earn Physician. 2004 Mar; 50: 425–33Google Scholar
Henderson, D.C.Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry. 2001; 62(Suppl 23): 39–44Google ScholarPubMed
Jin, H.Meyer, J.M.Jeste, D.V.Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of45 published cases. Ann Clin Psychiatry. 2002; 14(1): 59–64CrossRefGoogle Scholar
Koller, E.A.Schneider, B.Bennett, K.Dubitsky, G.Clozapineassociated diabetes. Am J Med. 2001; 111: 716–23CrossRefGoogle ScholarPubMed
Koller, E.Doraiswamy, P.M.Olanzpine-associated diabetes mellitus. Pharmacotherapy. 2002; 22: 841–52CrossRefGoogle ScholarPubMed
Koller, E.A.Cross, J.T.Doraiswamy, P.M.Schneider, B.S.Risperidoneassociated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003; 23: 735–44CrossRefGoogle ScholarPubMed
Kornegay, C.J.Vasilakis-Scaramozza, C.Jick, H.Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002; 63: 758–62CrossRefGoogle ScholarPubMed
Koro, C.E.Fedder, D.O.L'Italien, G.J.Weiss, S.S.Magder, L.S.Kreyenbuhl, J., et al.Assessment of independent effect of olanzapine and risperidone on risk of diabetes: population based nested casecontrol study. BMJ. 2002; 325: 243–7CrossRefGoogle Scholar
Lindenmayer, J.-P.Czobor, P.Volavka, J.Citrome, L.Sheitman, B.McEvoy, J.P., et al.Changes in glucose and cholesterol; levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003; 160: 290–6CrossRefGoogle ScholarPubMed
Mukherjee, S.Decina, P.Bocola, V.Saraceni, F.Scapicchio, P.Diabetes Mellitus in Schizophrenic patients. Comp Psychiatry. 1996; 37: 68–73CrossRefGoogle ScholarPubMed
Newcomer, J.W.Haupt, D.W.Fucetola, R.Melson, A.K.Schweiger, J.A.Cooper, B.P., et al.Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002; 59: 337–45CrossRefGoogle ScholarPubMed
Ryan, M.C.M.Thakore, J.H.Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002; 71: 239–57CrossRefGoogle ScholarPubMed
Sernyak, M.J.Leslie, D.L.Alarcon, R.D.Losonczy, M.F.Rosenheck, R.Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002; 159: 561–6CrossRefGoogle ScholarPubMed
Subramaniam, M.Chong, S.A.Pek, E.Diabetes mellitus and IGT in patients with schizophrenia. Can J Psychiatry. 2003 Jun;48(5): 345-7CrossRefGoogle Scholar
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26 (Suppl 1): S5–S20CrossRefGoogle Scholar
Wirshing, D.A.Boyd, J.A.Meng, L.R.Ballon, J.S.Marder, S.R.The effect of antipsychotics on glucose and lipids levels. J Clin Psychiatry. 2002; 63: 856–65CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.